SynthesisJournal of diabetes investigation2026

Comparative efficacy and safety of three fixed-ratio combination products in type 2 diabetes: A network meta-analysis.

What the trial testedas reported · 12,815 people · 2026

Not counted

1.7×1.1× to 2.6×

Bigger than 7 in 10 for adverse events & safety

As reported

OR 1.69, 95% CI 1.08–2.65

Not counted

1.7×1.2× to 2.4×

Bigger than 7 in 10 for adverse events & safety

As reported

OR 1.67, 95% CI 1.17–2.37

the abstract, start to end

Both IDegLira (OR = 1.69, 95% CI: 1.08-2.65) and iGlarLixi (OR = 1.67, 95% CI: 1.17-2.37) had a …

← favours treatmentfavours comparator →

could be chance

Adverse events & safety

OR 1.691.08–2.65

Adverse events & safety

OR 1.671.17–2.37

InsulinAdverse events & safety

1 / 3